SVB Securities analyst David Risinger lowered the firm’s price target on Amgen to $267 from $282 following the company’s January 31st Q4 results and 2023 guidance update. The firm keeps a Market Perform rating on the shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMGN: